<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562924</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS 15-010</org_study_id>
    <nct_id>NCT02562924</nct_id>
  </id_info>
  <brief_title>The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery</brief_title>
  <official_title>An Open-label, Prospective, Randomized, Pilot Clinical Study to Study the Efficacy of MEDIHONEY® Rinses Compared to Intranasal Corticosteroid Rinses in Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Vermont Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of MEDIHONEY® sinus rinses (alone or in combination
      with intranasal corticosteroids) vs. intranasal corticosteroid sinus rinses on mucosal
      healing and polyp recurrence in the post-operative period following functional endoscopic
      sinus surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with refractory CRSwNP, functional endoscopic sinus surgery (FESS), is intended
      to restore physiologic sinus ventilation and drainage, which can facilitate the gradual
      resolution of mucosal disease. However, because FESS does not directly treat the underlying
      inflammatory disorder, a successful sinus surgery must be followed by medical maintenance
      therapy to control inflammatory processes.

      The current mainstay of treatment of CRSwNP includes antibiotics and topical and systemic
      steroids. There is evidence that administration of systemic steroids in the postoperative
      period for patients who have polyps may have a significant impact on their postoperative
      course. However, the chance of significant side effects increases with the dose and duration
      of treatment and therefore the minimum dose necessary to control the disease should be given.
      Antibiotics also have their limited but documented side effects and can induce resistance.

      A semi-natural product like manuka honey (brand name MEDIHONEY®), with antibacterial and
      anti-inflammatory properties, might prove as a useful alternative since it has no major
      adverse events documented in the literature, does not induce resistance and is effective
      against resistant pathogens common in this patient population.

      This study is a prospective, randomized, pilot clinical trial that will determine if the use
      of MEDIHONEY® sinus rinses (alone or in combination with intranasal steroids) in the
      postoperative period enhances recovery and prevents polyp recurrence in patients after
      functional endoscopic sinus surgery (FESS), compared with the standard regimen of topical
      corticosteroid sinus rinses. The study will collect and compare subjective and objective
      efficacy assessments of both types of rinses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lund-Kennedy Endoscopic Scores</measure>
    <time_frame>119 days</time_frame>
    <description>Characteristics of each sinonasal cavity are assessed endoscopically to provide a score based on polyp disease, mucosal edema/crusting/scarring and nasal secretions. A score is provided for the left and right. The scores are totaled to provide a number between 0 and 20.
Polyps: 0 = absence of polyp; 1 = polyps in middle meatus only; 2 = polyps beyond middle meatus Edema: 0 = absent; 1 = mild; 2 = severe Discharge: 0 = no discharge; 1 = clear, thin discharge; 2 = thick, purulent discharge Scarring: 0 = absent; 1 = mild; 2 = severe Crusting: 0 = absent; 1 = mild; 2 = severe
This scoring system has since been the instrument of choice to endoscopically evaluate outcomes of interventions in non-neoplastic sinonasal disease prospectively over time in research and clinical practice. The higher the score, the worse the outcome. Endoscopy scores from the 3 study groups are compared for the average unit change between baseline and day 119.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal Drainage Cultures</measure>
    <time_frame>35 days</time_frame>
    <description>Nasal drainage cultures from the 3 study groups will be compared for the average percent change between a patient's positive intraoperative cultures compared to the patient's cultures at day 35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sinonasal Outcome Test (SNOT-22) Questionnaire Score</measure>
    <time_frame>119 days</time_frame>
    <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be). The overall score can theoretically range from 0 to 110, with higher scores reflecting more severe quality of life impairment as subjectively reported by the patient. Overall SNOT-22 scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SNOT-22 Nasal Symptom Scores</measure>
    <time_frame>119 days</time_frame>
    <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be).
The first seven questions relate to nasal symptoms. The nasal symptoms score is calculated by summing the scores for these first seven questions. The range is 0 to 35. Higher scores reflect more severe quality of life impairment as subjectively reported by the patient. The nasal symptom scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Chronic Sinusitis</condition>
  <condition>Nasal Polyposis</condition>
  <arm_group>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 0-7: Same as 1a;
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Days 0-7: Same as 1a.;
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MEDIHONEY®</intervention_name>
    <description>MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties</description>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Topical steroid</description>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline sinus rinse</intervention_name>
    <description>8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle</description>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Post-operatively, 40 mg daily for 7 days</description>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic sinus surgery</intervention_name>
    <description>Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage</description>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nasal saline spray</intervention_name>
    <description>saline nasal mist every hour while awake</description>
    <arm_group_label>Budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® and budesonide rinse group</arm_group_label>
    <arm_group_label>MEDIHONEY® rinse alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Age 18 years or older;

        2. Diagnosis of CRSwNP based on the following criteria:

          -  Pattern of symptoms:

             i. Symptoms present for ≥12 wk

          -  Symptoms for diagnosis: Requires ≥2 of the following symptoms:

             i. Anterior and/or posterior mucopurulent drainage; ii. Nasal obstruction; iii. Facial
             pain/pressure/fullness;

          -  Objective documentation: Requires both:

               1. Endoscopy to verify the presence of polyps in middle meatus and document presence
                  of inflammation, such as discolored mucus or edema of middle meatus or ethmoid
                  area; and

               2. Evidence of rhinosinusitis on imaging by CT (1 obvious polypoid tissue or sinus
                  opacification and/or at least 2mm of mucosal thickening).

          -  Failed medical management (i.e. refractory CRSwNP) and eligible for FESS.

        Exclusion Criteria:

          1. Contraindications to oral prednisone or known hypersensitivity to any study
             medications;

          2. Churg Strauss disorder;

          3. abnormalities of mucociliary clearance (cystic fibrosis, primary ciliary dyskinesia
             and Young's syndrome);

          4. Diagnosed immunodeficiency;

          5. Aspirin-induced asthma (ASA) (aka Samter triad) (a triad of asthma, aspirin and NSAID
             sensitivity, and nasal/ethmoidal polyposis).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary P Landrigan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vermont Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>September 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2019</results_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont Medical Center</investigator_affiliation>
    <investigator_full_name>Gary Landrigan, MD</investigator_full_name>
    <investigator_title>Associate Professor of Surgery, Division of Otolaryngology, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>MEDIHONEY</keyword>
  <keyword>Chronic Rhinosinusitis With Nasal Polyposis</keyword>
  <keyword>Functional Endoscopic Sinus Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02562924/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02562924/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All subjects were enrolled prior to surgery (day 0). Days 0-7 all subjects were treated with oral prednisone once daily, nasal saline irrigation four times daily, and nasal saline misting hourly while awake. Assignment to each arm occurred on day 7. Three enrolled subjects withdrew prior to assignment because they elected to not undergo surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Budesonide Rinse Group</title>
          <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray hourly while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.
Budesonide: Topical steroid Normal saline sinus rinse: 8 oz or 4 oz normal saline with NeilMed sinus rinse bottle Prednisone: Post-operatively 40 mg daily for 7 days Endoscopic sinus surgery: Surgery to debride polyps and establish adequate sinus drainage Nasal saline spray: saline nasal mist every hour while awake</description>
        </group>
        <group group_id="P2">
          <title>MEDIHONEY® Rinse Alone Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i until day 182
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182
MEDIHONEY®: A seminatural product with antibacterial and anti-inflammatory properties</description>
        </group>
        <group group_id="P3">
          <title>MEDIHONEY® and Budesonide Rinse Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Budesonide Rinse Group</title>
          <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray hourly while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.
Budesonide: Topical steroid Normal saline sinus rinse: 8 oz or 4 oz normal saline with NeilMed sinus rinse bottle Prednisone: Post-operatively 40 mg daily for 7 days Endoscopic sinus surgery: Surgery to debride polyps and establish adequate sinus drainage Nasal saline spray: saline nasal mist every hour while awake</description>
        </group>
        <group group_id="B2">
          <title>MEDIHONEY® Rinse Alone Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i until day 182
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182
MEDIHONEY®: A seminatural product with antibacterial and anti-inflammatory properties</description>
        </group>
        <group group_id="B3">
          <title>MEDIHONEY® and Budesonide Rinse Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="19"/>
                    <measurement group_id="B2" value="51" spread="14"/>
                    <measurement group_id="B3" value="58" spread="8"/>
                    <measurement group_id="B4" value="56" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Former Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Asthma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Environmental Allergies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Bronchiectasis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lund-Mackay Radiographic Score</title>
          <description>Radiographic scoring system based on pre-operative CT scan. Each sinus (anterior ethmoid, posterior ethmoid, maxillary, frontal, sphenoid) on the left and right are given a score of 0, 1 or 2 for no abnormality, partial opacification, and total opacification, respectively. Additionally, the right and left osteomeatal complexes are scored 0 or 2 for non-obstructed or obstructed, respectively. These values are summed, and a score between 0 and 24 is assigned. The higher the score, the worse the baseline disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="6.6"/>
                    <measurement group_id="B2" value="14.8" spread="5.6"/>
                    <measurement group_id="B3" value="18.3" spread="5.2"/>
                    <measurement group_id="B4" value="15.6" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Surgery Score</title>
          <description>Score on a scale of 0 to 14 to describe the extent of surgery performed. One point is assigned if that procedure is performed. The 7 possible procedures include anterior ethmoidectomy, frontal recess surgery, middle meatal antrostomy, posterior ethmoidectomy, reduction of middle turbinate, sphenoidectomy, uncinectomy. Scores are assigned for the left and right separately (up to 7 points on each side). A higher score indicates that more surgery was performed.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="1.0"/>
                    <measurement group_id="B2" value="13.0" spread="1.0"/>
                    <measurement group_id="B3" value="13.5" spread="0.9"/>
                    <measurement group_id="B4" value="13.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Lund-Kennedy Endoscopic Scores</title>
        <description>Characteristics of each sinonasal cavity are assessed endoscopically to provide a score based on polyp disease, mucosal edema/crusting/scarring and nasal secretions. A score is provided for the left and right. The scores are totaled to provide a number between 0 and 20.
Polyps: 0 = absence of polyp; 1 = polyps in middle meatus only; 2 = polyps beyond middle meatus Edema: 0 = absent; 1 = mild; 2 = severe Discharge: 0 = no discharge; 1 = clear, thin discharge; 2 = thick, purulent discharge Scarring: 0 = absent; 1 = mild; 2 = severe Crusting: 0 = absent; 1 = mild; 2 = severe
This scoring system has since been the instrument of choice to endoscopically evaluate outcomes of interventions in non-neoplastic sinonasal disease prospectively over time in research and clinical practice. The higher the score, the worse the outcome. Endoscopy scores from the 3 study groups are compared for the average unit change between baseline and day 119.</description>
        <time_frame>119 days</time_frame>
        <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Rinse Group</title>
            <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray hourly while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.
Budesonide: Topical steroid Normal saline sinus rinse: 8 oz or 4 oz normal saline with NeilMed sinus rinse bottle Prednisone: Post-operatively 40 mg daily for 7 days Endoscopic sinus surgery: Surgery to debride polyps and establish adequate sinus drainage Nasal saline spray: saline nasal mist every hour while awake</description>
          </group>
          <group group_id="O2">
            <title>MEDIHONEY® Rinse Alone Group</title>
            <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i until day 182
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182
MEDIHONEY®: A seminatural product with antibacterial and anti-inflammatory properties</description>
          </group>
          <group group_id="O3">
            <title>MEDIHONEY® and Budesonide Rinse Group</title>
            <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lund-Kennedy Endoscopic Scores</title>
          <description>Characteristics of each sinonasal cavity are assessed endoscopically to provide a score based on polyp disease, mucosal edema/crusting/scarring and nasal secretions. A score is provided for the left and right. The scores are totaled to provide a number between 0 and 20.
Polyps: 0 = absence of polyp; 1 = polyps in middle meatus only; 2 = polyps beyond middle meatus Edema: 0 = absent; 1 = mild; 2 = severe Discharge: 0 = no discharge; 1 = clear, thin discharge; 2 = thick, purulent discharge Scarring: 0 = absent; 1 = mild; 2 = severe Crusting: 0 = absent; 1 = mild; 2 = severe
This scoring system has since been the instrument of choice to endoscopically evaluate outcomes of interventions in non-neoplastic sinonasal disease prospectively over time in research and clinical practice. The higher the score, the worse the outcome. Endoscopy scores from the 3 study groups are compared for the average unit change between baseline and day 119.</description>
          <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="3.1"/>
                    <measurement group_id="O2" value="-1.5" spread="4.6"/>
                    <measurement group_id="O3" value="-6.9" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Drainage Cultures</title>
        <description>Nasal drainage cultures from the 3 study groups will be compared for the average percent change between a patient's positive intraoperative cultures compared to the patient's cultures at day 35.</description>
        <time_frame>35 days</time_frame>
        <population>This secondary objective describes analyzing quantitative changes in microbiology between day of surgery and post-operative day 35. These data were not collected, but rather the qualitative data (which microorganisms were present) were. Therefore we are not able to complete analysis on this secondary objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Rinse Group</title>
            <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
          </group>
          <group group_id="O2">
            <title>MEDIHONEY® Rinse Alone Group</title>
            <description>Days 0-7: Same as 1a;
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
          </group>
          <group group_id="O3">
            <title>MEDIHONEY® and Budesonide Rinse Group</title>
            <description>Days 0-7: Same as 1a.;
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Drainage Cultures</title>
          <description>Nasal drainage cultures from the 3 study groups will be compared for the average percent change between a patient's positive intraoperative cultures compared to the patient's cultures at day 35.</description>
          <population>This secondary objective describes analyzing quantitative changes in microbiology between day of surgery and post-operative day 35. These data were not collected, but rather the qualitative data (which microorganisms were present) were. Therefore we are not able to complete analysis on this secondary objective.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sinonasal Outcome Test (SNOT-22) Questionnaire Score</title>
        <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be). The overall score can theoretically range from 0 to 110, with higher scores reflecting more severe quality of life impairment as subjectively reported by the patient. Overall SNOT-22 scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
        <time_frame>119 days</time_frame>
        <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Rinse Group</title>
            <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray hourly while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.
Budesonide: Topical steroid Normal saline sinus rinse: 8 oz or 4 oz normal saline with NeilMed sinus rinse bottle Prednisone: Post-operatively 40 mg daily for 7 days Endoscopic sinus surgery: Surgery to debride polyps and establish adequate sinus drainage Nasal saline spray: saline nasal mist every hour while awake</description>
          </group>
          <group group_id="O2">
            <title>MEDIHONEY® Rinse Alone Group</title>
            <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i until day 182
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182
MEDIHONEY®: A seminatural product with antibacterial and anti-inflammatory properties</description>
          </group>
          <group group_id="O3">
            <title>MEDIHONEY® and Budesonide Rinse Group</title>
            <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sinonasal Outcome Test (SNOT-22) Questionnaire Score</title>
          <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be). The overall score can theoretically range from 0 to 110, with higher scores reflecting more severe quality of life impairment as subjectively reported by the patient. Overall SNOT-22 scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
          <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.8" spread="20.2"/>
                    <measurement group_id="O2" value="-15.3" spread="27.4"/>
                    <measurement group_id="O3" value="-25.6" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SNOT-22 Nasal Symptom Scores</title>
        <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be).
The first seven questions relate to nasal symptoms. The nasal symptoms score is calculated by summing the scores for these first seven questions. The range is 0 to 35. Higher scores reflect more severe quality of life impairment as subjectively reported by the patient. The nasal symptom scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
        <time_frame>119 days</time_frame>
        <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
        <group_list>
          <group group_id="O1">
            <title>Budesonide Rinse Group</title>
            <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray q 1 hour while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID (twice daily) c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
          </group>
          <group group_id="O2">
            <title>MEDIHONEY® Rinse Alone Group</title>
            <description>Days 0-7: Same as 1a;
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of the MEDIHONEY®rinse once daily. Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.</description>
          </group>
          <group group_id="O3">
            <title>MEDIHONEY® and Budesonide Rinse Group</title>
            <description>Days 0-7: Same as 1a.;
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID.
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SNOT-22 Nasal Symptom Scores</title>
          <description>The SNOT-22 consists of 22 questions; items 1 to 12 represent the physical problems associated with rhinosinusitis, items 13 to 18 represent the functional limitations, and items 20 to 22 represent the emotional consequences. Each question is scored by the patient from 0 (no problem) to 5 (the problem is as bad as it can be).
The first seven questions relate to nasal symptoms. The nasal symptoms score is calculated by summing the scores for these first seven questions. The range is 0 to 35. Higher scores reflect more severe quality of life impairment as subjectively reported by the patient. The nasal symptom scores from the 3 study groups are compared for the average change in score from baseline to day 119.</description>
          <population>The population analyzed for this outcome is the population of participants for which we had data points at day 119. Please note that this is different than the number of participants that completed the study (Budesonide: 13 enrolled, 11 analyzed; MEDIHONEY: 12 enrolled, 6 analyzed; MEDIHONEY and budesonide: 12 enrolled, 9 analyzed).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="7.0"/>
                    <measurement group_id="O2" value="-5.3" spread="15.5"/>
                    <measurement group_id="O3" value="-11.7" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was recorded in the form of a modified version of the Common Toxicity Criteria for Adverse Events (CTCAE). This was done at each visit from baseline (pre-surgery) to the 6th visit on day 182.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Budesonide Rinse Group</title>
          <description>1a. Days 0-7: 40 mg prednisone daily, saline sinus rinse 4 times daily, nasal saline spray hourly while awake b. Days 7-91: 8oz saline/budesonide sinus rinse BID c. After day 91: i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182.
Budesonide: Topical steroid Normal saline sinus rinse: 8 oz or 4 oz normal saline with NeilMed sinus rinse bottle Prednisone: Post-operatively 40 mg daily for 7 days Endoscopic sinus surgery: Surgery to debride polyps and establish adequate sinus drainage Nasal saline spray: saline nasal mist every hour while awake</description>
        </group>
        <group group_id="E2">
          <title>MEDIHONEY® Rinse Alone Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline sinus rinse followed with 0.5oz of MEDIHONEY® in 50 cc of normal saline
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse BID. Continue until day 182 ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz saline rinse followed with the 50cc of MEDIHONEY® rinse once daily.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 1.c.i until day 182
In case endoscopy shows no polyps, edema and discharge: Continue as per 1.c.ii till day 182
MEDIHONEY®: A seminatural product with antibacterial and anti-inflammatory properties</description>
        </group>
        <group group_id="E3">
          <title>MEDIHONEY® and Budesonide Rinse Group</title>
          <description>Days 0-7: Same as 1a
Days 7-91: 8oz saline/budesonide sinus rinse followed by 0.5oz of MEDIHONEY® in 50 cc of normal saline BID
After day 91:
i. In case endoscopy shows any polyps, edema or discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse BID. Continue with this regimen till day 182.
ii. In case endoscopy shows no polyps, edema and discharge: Decrease volume to 4 oz budesonide/saline rinse followed with 50cc of the MEDIHONEY® rinse once a day.
Reevaluate at day 119:
In case endoscopy shows any polyps, edema or discharge: Return to the initial regimen as per 3.c.i till day 182.
In case endoscopy shows no polyps, edema and discharge: Continue as per 3.c.ii till day 182.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration (anxiety)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of this study include: non-blinded study, high drop-out rate in one study arm, and lack of quantitative data for sinus cultures.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Daniel Gerges</name_or_title>
      <organization>University of Vermont Medical Center</organization>
      <phone>8028474535</phone>
      <email>daniel.gerges@uvmhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

